Court rules on PhRMA lawsuit regarding Medicare drug price negotiations
The Hill · August 27, 2026Original source ↗
What happened
A federal appeals court dismissed a lawsuit from the pharmaceutical industry against the Medicare drug price negotiation program. The court found that drug manufacturers do not have the right to dictate the prices at which they sell to Medicare.
Why it matters
This ruling may impact the cost of prescription drugs for Medicare recipients and the pharmaceutical industry.
How this story affects people
How does this story affect you if you are a Medicare recipient?
This ruling could lower the cost of prescription drugs for you, as it allows Medicare to negotiate prices directly with drug manufacturers. This may result in more affordable medications and improved access to necessary treatments.
How does this story affect you if you work in the pharmaceutical industry?
This decision may impact your company's pricing strategies and revenue models, as it restricts your ability to set prices for Medicare sales. Consequently, this could lead to adjustments in business operations or investment in research and development.
Want this written about you?
The breakdown above is the shared version, for kinds of people. In the app, Ripple uses your job, your city, and your family, then writes that part about you.
Get your Ripple